Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Proqr Therapeutics (PRQR)

Proqr Therapeutics (PRQR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 144,812
  • Shares Outstanding, K 81,355
  • Annual Sales, $ 7,050 K
  • Annual Income, $ -30,430 K
  • 60-Month Beta 0.39
  • Price/Sales 20.77
  • Price/Cash Flow N/A
  • Price/Book 4.21
Trade PRQR with:

Options Overview Details

View History
  • Implied Volatility 298.93% ( +158.65%)
  • Historical Volatility 43.18%
  • IV Percentile 87%
  • IV Rank 37.88%
  • IV High 743.78% on 10/04/23
  • IV Low 27.68% on 05/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 16,551
  • Open Int (30-Day) 16,399

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.12
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.15
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7000 +1.76%
on 09/18/24
2.1900 -21.00%
on 08/23/24
-0.3700 (-17.62%)
since 08/20/24
3-Month
1.6100 +7.45%
on 07/03/24
2.3500 -26.38%
on 08/15/24
+0.0200 (+1.17%)
since 06/20/24
52-Week
1.1100 +55.86%
on 10/27/23
3.2900 -47.42%
on 01/17/24
+0.2500 (+16.89%)
since 09/20/23

Most Recent Stories

More News
ProQR: Q2 Earnings Snapshot

ProQR: Q2 Earnings Snapshot

PRQR : 1.7300 (-2.81%)
ProQR: Q3 Earnings Snapshot

ProQR: Q3 Earnings Snapshot

PRQR : 1.7300 (-2.81%)
ProQR: Q2 Earnings Snapshot

ProQR: Q2 Earnings Snapshot

PRQR : 1.7300 (-2.81%)
ProQR: Q1 Earnings Snapshot

ProQR: Q1 Earnings Snapshot

PRQR : 1.7300 (-2.81%)
Why Shares of ProQR Therapeutics Dropped on Wednesday

The clinical-stage biotech released fourth-quarter and full-year earnings.

LLY : 921.49 (+0.70%)
PRQR : 1.7300 (-2.81%)
Lilly and ProQR to Expand RNA Editing Collaboration

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion of their licensing and...

LLY : 921.49 (+0.70%)
PRQR : 1.7300 (-2.81%)
ProQR: Q3 Earnings Snapshot

ProQR: Q3 Earnings Snapshot

PRQR : 1.7300 (-2.81%)
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology platform across...

PRQR : 1.7300 (-2.81%)
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates

Annual General Meeting of Shareholders to be held on June 30, 2022René Beukema joins management team as Chief Corporate Development Officer and General...

PRQR : 1.7300 (-2.81%)
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated...

PRQR : 1.7300 (-2.81%)

Business Summary

ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the...

See More

Key Turning Points

3rd Resistance Point 1.8900
2nd Resistance Point 1.8500
1st Resistance Point 1.7900
Last Price 1.7300
1st Support Level 1.6900
2nd Support Level 1.6500
3rd Support Level 1.5900

See More

52-Week High 3.2900
Fibonacci 61.8% 2.4572
Fibonacci 50% 2.2000
Fibonacci 38.2% 1.9428
Last Price 1.7300
52-Week Low 1.1100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar